In summary, our study has identified the TMEM45A/AKT/mTOR axis as a mediator of palbociclib resistance in breast cancer by promoting glycolysis and EMT in BRCA cells, highlighting its potential as a therapeutic target. Here, TMEM45A is linked to breast carcinoma.